Nisa Investment Advisors
CRVS icon

Nisa Investment Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Nisa Investment Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.09K Sell
207
-2,398
-92% -$33.3K ﹤0.01% 2686
2026
Q1 		$38.1K Buy
+2,605
New +$41.6K ﹤0.01% 1787

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nisa Investment Advisors's CRVS Position: Q2 2026 in Review

Nisa Investment Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 92% in Q2 2026, selling an estimated $33.3K and leaving 207 shares worth $3.09K. The position accounts for ﹤0.01% of the portfolio, ranked #2686.

Nisa Investment Advisors first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. The position peaked at $38.1K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Nisa Investment Advisors held 207 shares of Corvus Pharmaceuticals worth $3.09K as of Q2 2026.
  • Nisa Investment Advisors sold 2,398 Corvus Pharmaceuticals shares in Q2 2026, an estimated $33.3K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2686 holding.
  • Nisa Investment Advisors first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Nisa Investment Advisors's Corvus Pharmaceuticals position peaked at $38.1K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.